Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens
Public ClinicalTrials.gov record NCT01406938. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Multicenter Study of Subcutaneous Secukinumab, Assessing Psoriasis Area and Severity Index (PASI) Response and Maintenance of Response in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis on Either a Fixed Dose Regimen or on a Retreatment at Start of Relapse Regimen
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will assess the safety and efficacy of two different doses and two different dose regimens of subcutaneous secukinumab in patients that have moderate to severe, chronic, plaque-type psoriasis.
Study identification
- NCT ID
- NCT01406938
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 967 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2011 (Type not available)
- Primary completion
- May 2013 (Actual)
- Completion
- May 2013 (Actual)
- Last update posted
- May 19, 2015
2011 – 2013
United States locations
- U.S. sites
- 33
- U.S. states
- 17
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Fresno | California | 93710 | — |
| Novartis Investigative Site | Pasadena | California | 91105 | — |
| Novartis Investigative Site | Sacramento | California | 95817 | — |
| Novartis Investigative Site | San Francisco | California | 94118 | — |
| Novartis Investigative Site | Jacksonville | Florida | 32204 | — |
| Novartis Investigative Site | Jacksonville | Florida | 32216 | — |
| Novartis Investigative Site | Miami | Florida | 33136 | — |
| Novartis Investigative Site | Naples | Florida | 34119 | — |
| Novartis Investigative Site | South Miami | Florida | 33143 | — |
| Novartis Investigative Site | West Palm Beach | Florida | 33409 | — |
| Novartis Investigative Site | Atlanta | Georgia | 30342 | — |
| Novartis Investigative Site | Champaign | Illinois | 61820 | — |
| Novartis Investigative Site | Skokie | Illinois | 60077 | — |
| Novartis Investigative Site | Springfield | Illinois | 62703 | — |
| Novartis Investigative Site | Indianapolis | Indiana | 46256 | — |
| Novartis Investigative Site | Overland Park | Kansas | 66215 | — |
| Novartis Investigative Site | Owensboro | Kentucky | 42301 | — |
| Novartis Investigative Site | Boston | Massachusetts | 02111 | — |
| Novartis Investigative Site | Fridley | Minnesota | 55432 | — |
| Novartis Investigative Site | St Louis | Missouri | 63117 | — |
| Novartis Investigative Site | Henderson | Nevada | 89052 | — |
| Novartis Investigative Site | Las Vegas | Nevada | 89119 | — |
| Novartis Investigative Site | Verona | New Jersey | 07044 | — |
| Novartis Investigative Site | Greensboro | North Carolina | 27401 | — |
| Novartis Investigative Site | High Point | North Carolina | 27262 | — |
| Novartis Investigative Site | Winston-Salem | North Carolina | 27103 | — |
| Novartis Investigative Site | Anderson | South Carolina | 29621 | — |
| Novartis Investigative Site | Greer | South Carolina | 29651 | — |
| Novartis Investigative Site | Goodlettsville | Tennessee | 37072-2301 | — |
| Novartis Investigative Site | Dallas | Texas | 75230 | — |
| Novartis Investigative Site | Dallas | Texas | 75231 | — |
| Novartis Investigative Site | San Antonio | Texas | 78229 | — |
| Novartis Investigative Site | Salt Lake City | Utah | 84124 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 98 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01406938, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 19, 2015 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01406938 live on ClinicalTrials.gov.